1. Action of FR901228, a Novel Antitumor Bicyclic Depsipeptide Produced byChromo-bacterium violaceumNo. 968, on Ha-rasTransformed NIH3T3 Cells
- Author
-
Hidenori Nakajima, Toshio Goto, Yasuhiro Hori, Masakuni Okuhara, and Hirotsugu Ueda
- Subjects
Macromolecular Substances ,Stereochemistry ,Genes, myc ,Reversion ,Gene Expression ,Biology ,Transfection ,Peptides, Cyclic ,Applied Microbiology and Biotechnology ,Biochemistry ,Analytical Chemistry ,Mice ,chemistry.chemical_compound ,Transformation, Genetic ,Depsipeptides ,Animals ,Molecular Biology ,Cell Line, Transformed ,Cell Nucleus ,Depsipeptide ,Antibiotics, Antineoplastic ,Chromobacterium ,Cell Cycle ,Organic Chemistry ,RNA ,3T3 Cells ,DNA, Neoplasm ,General Medicine ,Blotting, Northern ,Flow Cytometry ,biology.organism_classification ,Molecular biology ,In vitro ,Anti-Bacterial Agents ,Kinetics ,Genes, ras ,Urinary Bladder Neoplasms ,chemistry ,Cell culture ,Growth inhibition ,Chromobacterium violaceum ,Cell Division ,Signal Transduction ,Biotechnology - Abstract
FR901228, a novel antitumor antibiotic, reversed the transformed morphology of the Ha-ras transformants, Ras-1 cells, and inhibited their growth. The reduction of c-myc expression was observed in FR901228-treated Ras-1 cells by RNA dot-blot hybridization. This reduction of c-myc expression and morphological reversion of the transformed cells to normal were correlated with growth inhibition (G0/G1 arrest in cell cycle).
- Published
- 1994
- Full Text
- View/download PDF